![]() ![]() TRULANCE provides a solution to the treatment gap currently experienced by patients suffering from IBS-C. “We know doctors are seeking alternatives to improve care for those Canadians with the often-debilitating symptoms of IBS-C.” “Bausch Health, Canada is proud to launch TRULANCE as the first therapy brought to the Canadian market in an area where there is a great unmet need for Canadian patients and for a condition for which the prevalence in Canada is one of the highest in the world,” said Ginette Gagné, interim president and general manager and vice president, Finance, Bausch Health, Canada. ![]() Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment, 3 but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms. TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, 2 and is the first treatment brought to market in Canada by the gastrointestinal division of the Company. (NYSE/TSX: BHC), (“Bausch Health” or the “Company”) today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE™ (plecanatide). LAVAL, QC, Febru– Bausch Health, Canada, part of Bausch Health Companies Inc. TRULANCE ® (plecanatide tablets) for Irritable Bowel Syndrome with Constipation in Adults Is now Available to Canadians to Help Meet Treatment Gap that leaves 70 Per cent of Patients Unsatisfied 1 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |